- The Data Monitoring Committee (DMC) has recommended Biophytis SA (NASDAQ:BPTS) to continue patient recruitment into part 2 of Phase 2-3 COVA Study in COVID-19, with the protocol unmodified after reviewing of safety data.
- The COVA clinical program is assessing Sarconeos (BIO101) in patients aged 45 and older hospitalized with severe respiratory manifestations of COVID-19.
- The independent DMC meeting was dedicated to analyzing safety data from the first 155 randomized patients.
- The DMC will review the efficacy data of the 155 patients in Q3 2021 as part of the second Interim analysis to recommend futility and final sample size.
- The Company is progressing to complete the recruitment of the 310 patients and report top-line results in Q4 of 2021.
- Price Action: BPTS shares closed 1.27% higher at $8.54 on Friday.
- Related content: Benzinga’s Full FDA Calendar.
Related Posts
EXCLUSIVE: COMSovereign Resumes High Volume Shipments Of Fastback Radio Products
COMSovereign Holding Corp. (NASDAQ: COMS) is announcing the resumption of volume shipments of its Fastback Networks radio products.
Raymond James Upgrades Shenandoah to Outperform, Announces $29 Price Target
Raymond James analyst Frank Louthan upgrades Shenandoah (NASDAQ:SHEN) from Market Perform to Outperform and announces $29 price target.
Darling Ingredients Raises $250M Via Add-On Debt Offering
Darling Ingredients Inc (NYSE:DAR) has launched an add-on offering of $250 million in aggregate principal amount of unsecured senior notes. The…